Plasma Citrulline Concentration in Tropical Enteropathy
Primary Purpose
Malabsorption Syndromes, Granulomatous Enteritis, Enteritis
Status
Completed
Phase
Locations
Zambia
Study Type
Observational
Intervention
Sponsored by
About this trial
This is an observational trial for Malabsorption Syndromes focused on measuring citrulline, malabsorption, Villous atrophy, enteropathy
Eligibility Criteria
Inclusion Criteria:
- histologically ascertained Tropical enteropathy
- Mixed HIV status
- Body mass index within normal range
Exclusion Criteria:
- Patients with surgical resection of stomach, duodenum or pancreas; or (UGI) bypass.
- Patients with other important disease, which may interfere with the study (especially diabetes and renal impairment). Alcoholism, drug abuse or any other circumstances, which may compromise the patient's ability to comply with the study requirements.
- Pregnancy
- Patients experiencing diarrhoea within one month since enrolment date
- Use of glucagon-like peptide 2 (GLP2), growth hormone (GH) or glutamine or triglycerides
- Coeliac Disease, Crohn's disease or infectious intestinal disease
- Patients on steroids or FANS
- Oral feeding>1.0-fold the estimated basal metabolic rate as assessed using Harris and Benedict equation
Sites / Locations
- Department of Medicine, University of Zambia School of Medicine, University Teaching Hospital
Outcomes
Primary Outcome Measures
postabsorptive plasma citrulline concentration
Secondary Outcome Measures
intestinal permeability ratio
Full Information
NCT ID
NCT00816842
First Posted
January 2, 2009
Last Updated
January 2, 2009
Sponsor
Azienda Ospedaliero-Universitaria di Parma
1. Study Identification
Unique Protocol Identification Number
NCT00816842
Brief Title
Plasma Citrulline Concentration in Tropical Enteropathy
Official Title
Plasma Citrulline as Quantitative Biomarker of HIV Associate Villous Atrophy in a Tropical Enteropathy Population
Study Type
Observational
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
October 1998 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
September 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Azienda Ospedaliero-Universitaria di Parma
4. Oversight
5. Study Description
Brief Summary
Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood stream. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with tropical enteropathy of mixed HIV status. The focus will be on the ability of the intestine to sustain the individual concerned from a nutritional standpoint. The investigators hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.
Detailed Description
Preliminary studies reported that plasma citrulline concentrations may be a reliable biochemical marker for intestinal dysfunction and absorptive enterocyte mass. The relationship between citrulline concentration and intestinal function has been supported in other studies including those examining rejection in small bowel allografts. Concentrations of citrulline are dramatically reduced in cases of mucosal damage (e.g. moderate graft rejection or viral enteritis)and strongly correlate (inversely) with severity on biopsy. Plasma citrulline concentration is lower also in patients with villous atrophy (24±13µmol/L)than in healthy subjects (40±10µmol/L)and patients with anorexia nervosa (39±9µmol/L).Experimental studies have been carried out also in assessing the value of citrulline as a marker for severity of small bowel epithelial damage from radiation and viral infections. The plasma citrulline was shown to be a simple, non invasive and sensitive essay to monitor and quantify radiation and/or chemotherapy induced small bowel damage in mice and humans. Otherwise, the literature on citrulline as a potential marker of intestinal and nutritional integrity is young and consistent data for specific conditions as for HIV enteropathy are missing.We hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malabsorption Syndromes, Granulomatous Enteritis, Enteritis, HIV Enteropathy, Ileal Diseases
Keywords
citrulline, malabsorption, Villous atrophy, enteropathy
7. Study Design
Primary Outcome Measure Information:
Title
postabsorptive plasma citrulline concentration
Time Frame
within two years since enrolment date
Secondary Outcome Measure Information:
Title
intestinal permeability ratio
Time Frame
within two years since enrolment date
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
histologically ascertained Tropical enteropathy
Mixed HIV status
Body mass index within normal range
Exclusion Criteria:
Patients with surgical resection of stomach, duodenum or pancreas; or (UGI) bypass.
Patients with other important disease, which may interfere with the study (especially diabetes and renal impairment). Alcoholism, drug abuse or any other circumstances, which may compromise the patient's ability to comply with the study requirements.
Pregnancy
Patients experiencing diarrhoea within one month since enrolment date
Use of glucagon-like peptide 2 (GLP2), growth hormone (GH) or glutamine or triglycerides
Coeliac Disease, Crohn's disease or infectious intestinal disease
Patients on steroids or FANS
Oral feeding>1.0-fold the estimated basal metabolic rate as assessed using Harris and Benedict equation
Study Population Description
Tropical enteropathy with mixed HIV status
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cinzia Papadia, MD
Organizational Affiliation
Azienda Ospedaliero-Universitaria di Parma
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alastair Forbes, BSc MD FRCP ILTM
Organizational Affiliation
University College London Hospitals
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Antonio Di Sabatino, MD
Organizational Affiliation
University of Pavia
Official's Role
Study Director
Facility Information:
Facility Name
Department of Medicine, University of Zambia School of Medicine, University Teaching Hospital
City
Lusaka
State/Province
Lusaka province
ZIP/Postal Code
P/B RW1X
Country
Zambia
12. IPD Sharing Statement
Learn more about this trial
Plasma Citrulline Concentration in Tropical Enteropathy
We'll reach out to this number within 24 hrs